An Open-label Extension Study of PSMA ADC 2301 in mCRPC
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
PSMA ADC 2301EXT is an open-label study to further assess the anti-tumor activity as measured
by radiographic imaging and biomarkers, safety and tolerability of Prostate Specific Membrane
Antigen Antibody Drug Conjugate (PSMA ADC) in subjects with mCRPC. Subjects who have
participated in the PSMA ADC 2301 study and who, in the opinion of the Principal Investigator
are likely to benefit from continued treatment with PSMA ADC are eligible for the PSMA ADC
2301 extension study. Subjects who are benefiting from treatment may be able to receive up to
an additional eight to sixteen doses (every 3 weeks) of PSMA ADC.